Weckermann Dorothea, Goppelt Marcus, Dorn Robert, Wawroschek Friedhelm, Harzmann Rolf
Department of Urology, Klinikum Augsburg, Augsburg, Germany.
BJU Int. 2006 Jun;97(6):1173-8. doi: 10.1111/j.1464-410X.2006.06166.x.
To investigate how many men with low-risk prostate cancer had positive lymph nodes detected by radio-guided surgery and whether they had a higher biochemical relapse rate after radical prostatectomy, because in such patients most urologists dispense with operative lymph node staging, as nomograms indicate only a low percentage of lymph node metastases.
The study included 474 men with a prostate-specific antigen (PSA) level of < or = 10 ng/mL, biopsy Gleason score of < or = 6 and positive biopsies in one (group 1, 315 men) or both lobes (group 2, 159 men); follow-up data were available in 357 men. Men with adjuvant radiation or hormone therapy before the occurrence of biochemical relapse were excluded.
Positive lymph nodes were detected in 17 men in group 1, and in 18 in group 2. In more than half of the patients (19/35) these nodes were found outside the region of standard lymphadenectomy. Men with node-positive disease had a higher biochemical relapse rate (P < 0.001). When the tumour was organ-confined and well differentiated in node-positive disease (Gleason score < or = 6) the biochemical relapse rate was lower than in men with higher tumour stage and grade.
When dissecting pelvic lymph nodes, extended or sentinel lymphadenectomy should be preferred. Removing the diseased nodes could improve the PSA progression-free survival, especially in well differentiated organ-confined disease.
研究通过放射性引导手术检测出的低风险前列腺癌男性患者中,有多少人的淋巴结呈阳性,以及他们在根治性前列腺切除术后生化复发率是否更高,因为在这类患者中,大多数泌尿科医生不进行手术淋巴结分期,因为列线图显示淋巴结转移的比例较低。
该研究纳入了474名前列腺特异性抗原(PSA)水平≤10 ng/mL、活检Gleason评分≤6且单叶活检阳性(第1组,315名男性)或双叶活检阳性(第2组,159名男性)的男性;357名男性有随访数据。排除在生化复发前接受辅助放疗或激素治疗的男性。
第1组有17名男性检测出淋巴结阳性,第2组有18名。超过半数患者(19/35)的这些淋巴结是在标准淋巴结清扫区域外发现的。淋巴结阳性疾病患者的生化复发率更高(P<0.001)。当淋巴结阳性疾病中的肿瘤局限于器官且分化良好(Gleason评分≤6)时,生化复发率低于肿瘤分期和分级较高的男性。
在解剖盆腔淋巴结时,应优先选择扩大或前哨淋巴结清扫术。切除患病淋巴结可改善无PSA进展生存期,尤其是在分化良好的器官局限性疾病中。